Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Broadwing Bio logo — Envisioning an End to Blindness

Broadwing Bio

Envisioning an End to Blindness

United States South San Francisco, United States 3 employees Biotechnology, Health and Wellness +1

General Information

Company Name Broadwing Bio
Location United States South San Francisco, United States +1
Employees 3
Industries Biotechnology, Health and Wellness, Pharmaceutical
Social

Get notified when Broadwing Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Broadwing Bio

Broadwing Bio is a biotechnology and pharmaceutical startup based in the United States, aiming to revolutionize the treatment of vision loss. With a focus on genetically validated targets, the company is committed to developing cutting-edge antibody therapies to combat common causes of blindness, particularly in glaucoma and geographic atrophy patients. Their slogan, "Envisioning an End to Blindness," encapsulates their ambition to make a meaningful impact in preserving eyesight. As of now, the company's founding date and specific investment details remain undisclosed, presenting an opportunity for potential venture capital investment. The pioneering work and promising vision of Broadwing Bio position it as an intriguing prospect for investors seeking to contribute to groundbreaking advancements in the biotechnology and pharmaceutical sectors.

Taxonomy: antibody therapies, vision loss, genetically validated targets, glaucoma, geographic atrophy, eyesight preservation, ophthalmology, genetic treatments

No funding data available for Broadwing Bio yet.

Get notified when Broadwing Bio raises funding

Broadwing Bio Alternatives & Competitors

Broadwing Bio vs
ElevateBio
ElevateBio United States

A cell and gene therapy company accelerating access to technologies and expertise to change the futu...

Series D
494 employees
Biotechnology
Broadwing Bio vs
Vineti
Vineti United States

Vineti’s Personalized Therapy Management (PTM®) drives and scales advanced therapies

Series C
20 employees
Biotechnology, Computing
Broadwing Bio vs
AveXis
AveXis

Specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting live...

Grant
Biotechnology, Health Care

FAQ About Broadwing Bio

Envisioning an End to Blindness
Broadwing Bio is headquartered in South San Francisco, United States.
Broadwing Bio operates in the following industries: Biotechnology, Health and Wellness, Pharmaceutical.
Broadwing Bio has approximately 3 employees.
Top alternatives and competitors to Broadwing Bio include ElevateBio, Vineti, AveXis, Xena Therapies, Eigen Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Broadwing Bio and ElevateBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Broadwing Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy